Trial Profile

A double-blind placebo-controlled Phase IIb trial evaluating evaluate the safety and tolerability of RJx-01 in COPD-related sarcopenia

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jun 2026 According to a Rejuvenate Biomed media release, company today that it has completed recruitment in this phase 2 trial MINT-COPD evaluating RJx-01, in patients with chronic obstructive pulmonary disease (COPD)-induced muscle weakness and sarcopenia
01 Jun 2026 According to a Rejuvenate Biomed media release, topline data from the trial expected by year-end 2026.
19 May 2025 According to a Rejuvenate Biomed media release, the first patient has been dosed

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com